| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KMO |
| Uniprot No | O15229 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-407aa |
| 氨基酸序列 | MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTR GRSINLALSHRGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAIPYG TKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMITVLG SDKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIP PKNGDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFEEFEKLLTS NDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFKSHCV LLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRI PDDHAISDLSMYNYIEKNMERFLHAIMPSTFIPLYTMVTFSRIRYHEAVQ RWHWQKR |
| 预测分子量 | 71 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于KMO(Kynurenine 3-Monooxygenase)重组蛋白的示例参考文献(内容为模拟示例，实际引用请核实真实文献)：
---
1. **文献名称**: "Expression and Purification of Recombinant Human Kynurenine 3-Monooxygenase in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 报道了通过大肠杆菌表达系统高效表达人源KMO重组蛋白的优化方法，包括His标签纯化步骤和酶活性验证，为后续功能研究提供工具。
2. **文献名称**: "Structural Insights into Kynurenine 3-Monooxygenase by Cryo-EM"
**作者**: Zhang Y, et al.
**摘要**: 利用冷冻电镜技术解析了重组KMO的三维结构，揭示了其底物结合域和辅酶FAD的作用机制，为靶向药物设计奠定基础。
3. **文献名称**: "KMO Inhibition in a Huntington’s Disease Model Using Recombinant Protein Screening"
**作者**: Campesan S, et al.
**摘要**: 通过重组KMO蛋白筛选小分子抑制剂，并在亨廷顿病果蝇模型中验证其神经保护作用，证明KMO作为治疗靶点的潜力。
4. **文献名称**: "Engineering Yeast for High-Yield Kynurenine 3-Monooxygenase Production"
**作者**: Lee J, et al.
**摘要**: 开发了基于毕赤酵母的重组KMO表达系统，优化培养条件后蛋白产量提升5倍，适用于大规模工业化制备。
---
**注意**：以上为模拟文献，实际研究需查阅PubMed、Web of Science等数据库获取真实信息。
**Background of KMO Recombinant Protein**
Kynurenine 3-monooxygenase (KMO), a mitochondrial flavoprotein monooxygenase, is a key enzyme in the kynurenine pathway (KP) of tryptophan metabolism. This pathway plays a critical role in regulating immune responses, neurotransmitter balance, and energy production. KMO catalyzes the conversion of kynurenine to 3-hydroxykynurenine, a reaction that influences the downstream production of neuroactive metabolites like quinolinic acid (a neurotoxic NMDA receptor agonist) and kynurenic acid (a neuroprotective glutamate antagonist). Dysregulation of KMO activity is implicated in neurodegenerative disorders (e.g., Alzheimer’s, Huntington’s), psychiatric conditions (e.g., depression, schizophrenia), and inflammatory diseases, making it a therapeutic target.
Recombinant KMO protein, produced via heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*), enables detailed biochemical and structural studies. Its recombinant form retains enzymatic activity and allows high-throughput screening of inhibitors or modulators for drug development. Advances in protein engineering and purification have improved stability and yield, facilitating crystallography and mechanistic analyses. Recent studies highlight KMO’s role in modulating neuroinflammation and oxidative stress, with animal models demonstrating that KMO inhibition ameliorates disease phenotypes.
The development of recombinant KMO also supports biomarker research, as KP imbalance correlates with disease progression. Challenges remain in optimizing its membrane-associated enzymatic properties *in vitro*, but ongoing innovations in recombinant technology continue to enhance its utility in both basic research and therapeutic exploration.
×
